What is the management plan for a patient with moderate mitral valve regurgitation, Grade I diastolic dysfunction, normal ejection fraction (EF), and no evidence of left ventricular hypertrophy (LVH) or aortic root dilatation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

ICD-10 Code for Moderate Mitral Regurgitation with Grade I Diastolic Dysfunction

The appropriate ICD-10 code is I34.0 (Nonrheumatic mitral [valve] insufficiency).

Primary Diagnosis Code

  • I34.0 is the specific code for nonrheumatic mitral valve regurgitation/insufficiency, which applies to this patient with moderate mitral regurgitation 1

Additional Relevant Codes to Consider

  • I50.32 (Chronic diastolic [congestive] heart failure) may be considered given the Grade I diastolic dysfunction, though this represents impaired relaxation rather than overt heart failure 1
  • If the patient has any symptoms of heart failure, I50.9 (Heart failure, unspecified) could be added as a secondary code 1

Management Approach for This Clinical Scenario

Surveillance Strategy

This patient requires regular echocardiographic monitoring every 1-2 years given the moderate mitral regurgitation with normal ejection fraction 1, 2. More frequent monitoring (every 6-12 months) should be implemented if there are dynamic changes or parameters approaching intervention thresholds 1, 2.

Key parameters to monitor include:

  • Left ventricular ejection fraction and end-systolic dimension (LVESD) 3
  • Left atrial volume index (threshold ≥60 mL/m²) 1, 2
  • Development of new atrial fibrillation 3
  • Pulmonary artery systolic pressure (threshold ≥50 mmHg) 1, 2
  • Progressive LV dilation on serial imaging 3

Current Management Recommendations

No surgical intervention is indicated at this time 2. The patient has moderate (not severe) MR with preserved LVEF (60-65%) and normal LV size without evidence of LVH 1, 2.

Medical management considerations:

  • No specific medical therapy is required for asymptomatic moderate MR with preserved LVEF 2
  • If hypertension is present, aggressive blood pressure control is essential as it can affect MR severity 2
  • The Grade I diastolic dysfunction does not require specific treatment beyond standard cardiovascular risk factor management 1

Critical Thresholds for Surgical Referral

Immediate surgical evaluation becomes necessary if any of the following develop 1, 3, 2:

  • Progression to severe MR with symptoms (NYHA Class II-IV) 1, 4
  • LVEF decreases to <60% with LVESD ≥40 mm 3, 2
  • New-onset atrial fibrillation secondary to MR 3, 2
  • Resting pulmonary artery systolic pressure exceeding 50 mmHg 1, 2
  • LA volume index reaching ≥60 mL/m² 1, 2

Important Clinical Caveats

The normal ejection fraction of 60-65% should not provide false reassurance 2. In the context of mitral regurgitation, EF is typically augmented by the low-impedance pathway into the left atrium, so an EF at the lower end of normal (60%) may actually reflect early ventricular dysfunction 2.

Regular surveillance is crucial as moderate MR can progress to severe MR over time 2. Serial imaging demonstrating progressive changes should prompt earlier referral even in asymptomatic patients 3, 2.

Special Consideration for Concomitant Surgery

If this patient requires cardiac surgery for another indication (e.g., coronary artery bypass grafting), concomitant mitral valve repair may be considered even for moderate MR 1, 2. This is a Class IIa recommendation when performed at experienced centers 1.

Preferred Intervention When Needed

When intervention eventually becomes necessary, mitral valve repair is strongly preferred over replacement 4, 2. Repair preserves LV function, avoids prosthetic valve complications, and improves long-term outcomes compared to replacement 3, 4.

Related Questions

What is the recommended management for a 77-year-old female with normal left ventricular (LV) systolic function, mild mitral valve regurgitation, and grade I diastolic dysfunction?
Are left ventricular hypertrophy, a dilated left atrium, and mild mitral and pulmonic regurgitation classified as high atherosclerotic cardiovascular disease (ASCVD) risk?
What is the management approach for a patient with moderate mitral regurgitation (MR) with an eccentric jet and a left ventricular ejection fraction (LVEF) of mildly reduced left ventricular function?
What is the best management approach for a patient with eccentric left ventricular hypertrophy, Grade 1 diastolic dysfunction, mitral sclerosis with mild mitral regurgitation, and aortic sclerosis?
Can you explain the echocardiogram findings (mild concentric left ventricular hypertrophy, ejection fraction 60‑65%, apical akinesis, mild aortic valve regurgitation, normal other chambers) in simple terms and recommend appropriate management?
What is the role of Ativan (lorazepam) nasal spray in managing seizures, particularly in patients with a history of epilepsy or at risk of recurrent seizures?
Why do I feel panicky immediately after taking Qelbree (viloxazine) for Attention Deficit Hyperactivity Disorder (ADHD) in the morning?
Is 40mg of Paxil (paroxetine) a suitable dose for a geriatric patient with potentially impaired renal function?
Can a higher dose of Qelbree (viloxazine) increase anxiety or improve mood regulation in a patient with Attention Deficit Hyperactivity Disorder (ADHD) and a history of anxiety symptoms?
Is tapering necessary when discontinuing dexamethasone (corticosteroid) 40 mg after a 5-day course?
What are the risks of performing an endoscopy on an 86-year-old female with potential comorbidities, such as cardiovascular disease, and possible use of medications like anticoagulants (blood thinners) or antiplatelet agents?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.